A study to assess the safety, tolerability and pharmacokinetics of tideglusib in subjects with hepatic impairment compared to healthy subjects.

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-516774-30-00

Acronym

AMO-02-MD-1-001

Enrollment

Registered

2024-10-09

Start date

Unknown

Completion date

2025-04-09

Last updated

2024-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy subjects, Hepatic impairment

None listed

Sex/Gender

All

Age

18 Years to 64 Years

Bulgaria

None listed

Source: EU CTIS · Data processed: Feb 4, 2026